How Does P21ras Transform Cells?
Overview
Authors
Affiliations
Oncogenic forms of p21ras are found in a wide range of human tumors. However, the mechanism by which p21ras transforms remains obscure. Genetic evidence has identified a domain of p21ras that is involved with interaction with an effector molecule required for transformation. Two proteins, GAP and the tumor suppressor NF1, interact with p21ras in this region but it is an unresolved puzzle whether either of these is the an unresolved puzzle whether either of these is the effector. After interaction with an effector, two downstream events--activation of protein kinase C and another pathway--are necessary for induction of DNA synthesis by oncogenic p21ras; however, morphological transformation does not require activation of protein kinase C.
Smorodinsky-Atias K, Goshen-Lago T, Goldberg-Carp A, Melamed D, Shir A, Mooshayef N Mol Biol Cell. 2015; 27(6):1026-39.
PMID: 26658610 PMC: 4791124. DOI: 10.1091/mbc.E15-07-0521.
Luo F, Poulogiannis G, Ye H, Hamoudi R, Dong G, Zhang W Int J Exp Pathol. 2013; 95(1):8-15.
PMID: 24354449 PMC: 3919644. DOI: 10.1111/iep.12064.
Clinical relevance of KRAS in human cancers.
Jancik S, Drabek J, Radzioch D, Hajduch M J Biomed Biotechnol. 2010; 2010:150960.
PMID: 20617134 PMC: 2896632. DOI: 10.1155/2010/150960.
LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer.
Li J, Zhang Z, Dai Z, Plass C, Morrison C, Wang Y Oncogene. 2003; 22(8):1243-6.
PMID: 12606951 PMC: 3438910. DOI: 10.1038/sj.onc.1206192.
Swisher S, Roth J Curr Oncol Rep. 2000; 2(1):64-70.
PMID: 11122826 DOI: 10.1007/s11912-000-0012-1.